AEHR · Aehr Test Systems

The thesis

Aehr Test Systems' $100.6 million effective backlog still supports its $130–150 million fiscal 2027 revenue guidance, but the shares closed at $54.89 on 30 October 2026, 62.3% below the 52-week high of $145.61. The first-quarter report after the close on 2 November 2026 decides whether the guidance holds. Aehr makes burn-in systems, which stress chips to weed out early failures before they ship.

The price case from the previous note has already failed. The shares closed at $63.33 on 19 October 2026 and at $54.89 on 30 October 2026, under the $55.00 invalidation level that note named. The shares have fallen 50.1% over three months, and the 14-day relative strength index (RSI), a momentum gauge where readings below 30 are usually called oversold, stood at 27.2 on 30 October 2026.

The narrative is maturing: the story is well known and still drawing orders, but the last order announcement was on 7 October 2026 and the shares have fallen since. The business case is untested until the numbers arrive.

Bullish and bearish views on Aehr Test Systems

The bull case on Aehr Test Systems (AEHR), in brief: A second AI program is ordering. The bear case: The price keeps breaking down.

Bull case

• A second AI program is ordering. On 7 October 2026 the company announced about $6 million of follow-on Sonoma orders, per Benzinga, from an unnamed hyperscaler for its second AI processor, with a production ramp expected in 2027.
• Backlog covers much of the guided year. The $100.6 million effective backlog reported on 14 July 2026 followed record fiscal fourth-quarter bookings of $60.7 million (SEC Form 8-K exhibit 99.1).
• Guidance includes profit. On 14 July 2026 the company guided fiscal 2027 non-GAAP (adjusted) pre-tax profit at 18%–22% of revenue, with about 70% of revenue from AI.
• Several end markets ordered this summer. Company releases show a $22 million AI-processor order on 12 August 2026, a silicon-photonics follow-on on 4 August 2026 and more than $8 million of silicon-carbide orders on 14 July 2026.
• Board adds data-center expertise. On 29 October 2026 Aehr named Vijay Rao, a former Meta infrastructure executive, to its board.
• Analyst targets sit far above the close. Investing.com listed a $128 consensus target in October 2026, with a range of $110 to $175 across five analysts. Jefferies' target is $175 (14 August 2026) and Oppenheimer's is $120 (10 September 2026).

Bear case

• The price keeps breaking down. The shares fell from $92.14 on 6 October 2026 to $54.89 on 30 October 2026, on adjusted daily closes. No company release since 8 October 2026 explains the decline.
• Quarterly revenue will be uneven. TipRanks' summary of the 14 July 2026 call reported management expecting a very strong second quarter from a $41 million April order. Investing.com put first-quarter consensus at $26.82 million of revenue on 5 October 2026, so a light first quarter is possible even if the year holds.
• Guidance far exceeds reported scale. Fiscal 2026 revenue was $50.0 million with a $7.1 million GAAP net loss, per the 14 July 2026 release.
• One customer drives AI demand. The 7 October 2026 order came from the existing lead hyperscale customer, so no second AI-processor production customer has been announced.
• Insiders have been steady sellers. Massive.com's insider page shows 13 insiders reported open-market sales of $63.3 million across 49 filings in the 12 months to 26 October 2026, with no open-market purchases.
• Issuance is possible. A $60 million at-the-market programme (8 April 2026) and a universal shelf (27 July 2026) allow share sales that surface only in filings.

Price setup

The last adjusted close was $54.89 on 30 October 2026. That is 62.3% under the 52-week high of $145.61 and 50.1% lower than three months earlier. RSI of 27.2 shows selling has been sustained, with no sign yet of a recovery.

The shares closed below the $55.00 level named in the previous note. A close below $48.00 would extend the slide, and a business result can override either level.

Crowding evidence has thinned on price but not on risk. Options implied a move of about 23.6% around the report, with 30-day implied volatility of 111.9% (Market Chameleon, 9 October 2026). AEHG, a 2x leveraged fund on the shares launched 26 June 2026, rebalances daily and can magnify moves in either direction. The report falls on 2 November 2026, the last session in this note's data window.

Catalysts, next 30 days

• ~9 November 2026, est.: quarterly report on SEC Form 10-Q. It would show remaining backlog and any at-the-market share sales in the quarter or after it.

Elapsed catalysts

• 2 November 2026: fiscal 2027 first-quarter results, after the close, call at 5:00 p.m. ET. Consensus was $26.82 million of revenue and $0.10 of earnings per share (Investing.com, 5 October 2026). Previews published later cite about $27.5 million and $0.11. The guidance statement, shipment timing for the $41 million April order and any second-customer comment matter more than the quarter itself. (passed 4d ago)

What would change the view

The case breaks if management cuts or withdraws the $130–150 million fiscal 2027 revenue guidance, or if backlog falls without new AI-processor bookings. It also breaks if the $41 million April order slips out of the second quarter by a meaningful amount.

On price, a daily close below $48.00 would extend the October decline and end the thesis. Evidence that would strengthen the case includes reaffirmed guidance with first-quarter revenue near consensus, or a production order from a second AI-processor customer. Filings showing at-the-market sales or a shelf takedown after the report would weigh on it.

What it trades with

Aehr trades with other test and burn-in equipment makers and with AI-chip demand, since about 70% of fiscal 2027 revenue is guided to come from AI. Its silicon-photonics and silicon-carbide lines tie it to optical and power-chip capital spending. The 2x leveraged fund AEHG adds daily-rebalancing flows that move the shares independently of those groups. No current theme cluster carries the name.